Clinical Trials Logo

Seroma clinical trials

View clinical trials related to Seroma.

Filter by:

NCT ID: NCT01358786 Completed - Seroma Clinical Trials

Seroma at the Donor Site of the TRAM Flap, With or Without Quilting Suture: A Comparative Study Using Ultrasound

STRAMQUSG
Start date: April 2009
Phase: Phase 1
Study type: Interventional

Patient undergoing breast reconstruction with lower abdominal flap, benefit when points are used for membership (between the aponeurosis of the abdominal flap and underlying muscles) for closing the donor area, where there is reduced incidence of complications.

NCT ID: NCT01267552 Completed - Breast Cancer Clinical Trials

Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer

Start date: July 2000
Phase: Phase 2/Phase 3
Study type: Interventional

To study the safety of not draining the axilla, after breast conserving surgery and full axillary lymphadenectomy.

NCT ID: NCT01188954 Withdrawn - Seroma Clinical Trials

Doxycycline Versus Standard Care to Prevent Seroma Formation

Start date: January 2010
Phase: N/A
Study type: Interventional

A seroma is a collection of fluid other than pus or blood which forms through the division of numerous lymphatic channels, which normally drain the interstitial space under the skin. These channels become disrupted during surgical procedure and lead to seroma formation. This collection of fluid causes pressure in the local area, patient discomfort, and provides unfortunately an excellent culture medium for bacteria. Seroma development has been previously described in femoral vessel groin cannulation dissections after surgery. Conventional therapy is limited to draining the fluid, sometimes more than once, until there is full resolution of the seroma. If fluid collection recurs at the surgical site, sclerosant therapy with agents such as doxycycline. Doxycycline has been found to be a cost effective agent used as a sclerosant, which belongs to tetracycline class of antibiotics. The investigators hypothesize that prophylactic use of doxycycline at the site of femoral cannulation will prevent or minimize the area of seroma formation as compared to standard care of patients. The aim is driven towards limiting patient discomfort and visits to the clinic and to improve clinical care.

NCT ID: NCT01112735 Completed - Seroma Clinical Trials

Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to compare the safety and efficacy of ARTISS versus standard of care in adhering tissue places and reducing seroma/hematoma formation in subjects undergoing abdominoplasty.

NCT ID: NCT00968318 Completed - Seroma Clinical Trials

Excision of Strip of Deep Fascia to Reduce Seroma Formation and Extrusion of Tissue Expanders

Start date: May 2006
Phase: N/A
Study type: Interventional

Tissue expansion has enjoyed a wide range of applications since the technique was popularized in the latter quarter of the last century. During the expansion process, subcutaneous fat liquefies, skin becomes thinner, muscles atrophy, blood inflow increases, and lymphatics get occluded. All these factors predispose to seroma formation and implant extrusion. A similar problem occurred with lymphoedema patients, and one of the lines of treatment was creation of a connection to the deep lymphatics to facilitate absorption of accumulated fluid. The same principle is to be extrapolated to patients having tissue expanders inserted in the neck and limbs and its effect is to be noted on the incidence of seroma .

NCT ID: NCT00852826 Completed - Seroma Clinical Trials

Evaluation of a Hemostatic and Sealing Agent to Prevent Surgical Complications After Axillary Lymphadenectomy

Start date: January 2008
Phase: Phase 4
Study type: Interventional

This study was intended to assess the value of a hemostatic and sealing agent, a collagen sponge coated with human coagulation factors (fibrinogen and thrombin) (TachoSil®), for decreasing occurrence of seroma after axillary lymphadenectomy.